FDA Internal Memo Attributes 10 Pediatric Deaths to COVID-19 Vaccines, Marking Major Agency Shift

Washington, D.C. — In a significant departure from its previous safety consensus, the U.S. Food and Drug Administration (FDA) has circulated an internal memo attributing the deaths of at least 10 children to COVID-19 vaccinations. The document, authored by Dr. Vinay Prasad, the agency’s Chief Medical and Scientific Officer, states that a recent agency review concluded these fatalities occurred “after and because of” the vaccine, primarily citing myocarditis (heart inflammation) as the suspected cause.

This development marks a pivotal and controversial shift in federal health policy under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., signalling a new direction for an agency that had previously characterized such adverse events as extremely rare and outweighed by the benefits of immunization.

The Internal Review Findings

The memo, which was distributed to agency staff on Friday and subsequently obtained by The New York Times, reveals that the FDA’s new analysis was led by Dr. Tracy Beth Hoeg, a senior FDA adviser. According to the document, the agency reviewed case reports and determined a causal link in a small cluster of pediatric cases.

“For the first time, the U.S. FDA will acknowledge that COVID-19 vaccines have killed American children,” Dr. Prasad wrote in the communication to staff. He described the findings as a “profound revelation” that necessitates an immediate re-evaluation of vaccine safety monitoring.

The memo suggests that the mechanism of death in these cases was vaccine-induced myocarditis, a condition involving inflammation of the heart muscle. While public health officials have long acknowledged a rare risk of myocarditis, particularly in adolescent males, previous assessments had consistently found the condition to be generally mild and self-limiting, with fatal outcomes being extraordinarily rare.

Notably, the memo did not disclose specific details regarding the ages of the children, their underlying health conditions, or the specific vaccine manufacturers involved (Pfizer-BioNTech or Moderna). The findings have not yet been published in a peer-reviewed medical journal.

A Shift in Federal Stance

The release of this internal conclusion represents a stark “U-turn” for the FDA. For years, the agency’s position—supported by data from the Centers for Disease Control and Prevention (CDC)—has been that the risk of death from COVID-19 infection far exceeds the risks associated with vaccination.

The current administration, however, has pledged to scrutinize vaccine safety data more aggressively. The appointment of Dr. Prasad, a vocal critic of previous pandemic policies and mandates, alongside the oversight of Secretary Kennedy, has ushered in a period of intense re-examination of pandemic-era interventions.

The memo indicates that the FDA plans to tighten oversight protocols, including a requirement for randomized studies for all population subgroups moving forward.

Expert Reactions and Skepticism

The memo has triggered immediate and polarized reactions within the medical community. While some argue this transparency is overdue, many infectious disease experts are calling for caution, characterizing the memo as “science by press release” due to the lack of public data.

Dr. Paul Offit, a vaccine expert at the Children’s Hospital of Philadelphia and a member of the FDA’s vaccine advisory committee, criticized the release for lacking essential context.

“This is an irresponsible way to deal with a very critical public health issue like vaccination and adverse events,” Dr. Offit said. He emphasized that without comparing these 10 deaths to the background rates of myocarditis caused by the virus itself, the data is incomplete. “We saw children admitted to our hospital with myocarditis from the virus,” Offit noted. “It was quite severe and caused admissions to the intensive care unit.”

Dr. Peter Marks, the former director of the FDA division that regulated vaccines, expressed surprise at the “clearly political tone” of Dr. Prasad’s communication. “I would not be surprised if the attributions turn out to be debatable, as these cases are often quite complex,” Marks stated, advocating for the case reports to be opened to broader scientific scrutiny before definitive conclusions are drawn.

Public Health Context and Implications

To place these findings in perspective, data from the American Academy of Pediatrics (AAP) indicates that approximately 2,100 children in the United States have died from COVID-19 since the start of the pandemic. Historically, the CDC has maintained that vaccination prevents severe outcomes, including Multisystem Inflammatory Syndrome in Children (MIS-C), a serious condition linked to the virus.

The central question for parents and pediatricians now is whether this new attribution of 10 deaths alters the risk-benefit calculus. For healthy children, particularly adolescents who are at highest risk for myocarditis, this news may deepen vaccine hesitancy.

The CDC’s Advisory Committee on Immunization Practices (ACIP) is expected to meet next week to discuss the broader childhood vaccine schedule. A newly formed subgroup, led by MIT management expert Retsef Levi, is also set to review the safety profile of mRNA vaccines specifically.

Conclusion

As the FDA prepares to formally acknowledge these findings, the medical community awaits the release of the raw data and case histories. For now, the disclosure highlights a growing fracture between the new federal health leadership and the established medical consensus, leaving healthcare providers and parents to navigate an increasingly complex landscape of safety information.

Medical Disclaimer:

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References:

• Primary Report: Jewett, C. (2025, November 28). “FDA attributes 10 children’s deaths to COVID vaccines.” The New York Times.

• Internal Agency Document: Prasad, V. (2025). Internal Memorandum to FDA Staff regarding Pediatric Vaccine Safety Review. U.S. Food and Drug Administration.

• Expert Commentary:

  • Dr. Paul Offit, Vaccine Education Center, Children’s Hospital of Philadelphia.

  • Dr. Peter Marks, Former Director, Center for Biologics Evaluation and Research (CBER), FDA.

• Statistical Data: American Academy of Pediatrics (AAP). “Children and COVID-19: State-Level Data Report” (2025).

FDA officials expected to present data they say links child deaths to Covid vaccine